BNP has several actions, including vasodilation which can decrease cardiac afterload, diuretic and natriuretic effects, and suppression of both sympathetic tone and the renin-angiotensin-aldosterone system. In the case of heart failure, BNP is primarily secreted by the ventricular myocardium to compensate for symptoms by promoting diuresis, natriuresis, vasodilation, and suppression of sympathetic tone and renin-angiotensin-aldosterone activity. Vasodilation of the peripheral vascular system leads to a decrease in afterload, reducing the force that the left ventricle has to contract against and lowering the risk of left ventricular failure progression. BNP also suppresses sympathetic tone and the RAAS, which would exacerbate heart failure symptoms, and contributes to natriuresis, aiding diuresis and improving dyspnea.

B-type natriuretic peptide (BNP) is a hormone that is primarily produced by the left ventricular myocardium in response to strain. Although heart failure is the most common cause of elevated BNP levels, any condition that causes left ventricular dysfunction, such as myocardial ischemia or valvular disease, may also raise levels. In patients with chronic kidney disease, reduced excretion may also lead to elevated BNP levels. Conversely, treatment with ACE inhibitors, angiotensin-2 receptor blockers, and diuretics can lower BNP levels.

BNP has several effects, including vasodilation, diuresis, natriuresis, and suppression of both sympathetic tone and the renin-angiotensin-aldosterone system. Clinically, BNP is useful in diagnosing patients with acute dyspnea. A low concentration of BNP (<100 pg/mL) makes a diagnosis of heart failure unlikely, but elevated levels should prompt further investigation to confirm the diagnosis. Currently, NICE recommends BNP as a helpful test to rule out a diagnosis of heart failure. In patients with chronic heart failure, initial evidence suggests that BNP is an extremely useful marker of prognosis and can guide treatment. However, BNP is not currently recommended for population screening for cardiac dysfunction.

BNP is primarily secreted by the ventricular myocardium in response to stretching, making it a valuable indicator of heart failure. While it can be used for screening and prognostic scoring, it is not secreted by the atrial endocardium, distal convoluted tubule, pulmonary artery endothelium, or renal mesangial cells.

B-type natriuretic peptide (BNP) is a hormone that is primarily produced by the left ventricular myocardium in response to strain. Although heart failure is the most common cause of elevated BNP levels, any condition that causes left ventricular dysfunction, such as myocardial ischemia or valvular disease, may also raise levels. In patients with chronic kidney disease, reduced excretion may also lead to elevated BNP levels. Conversely, treatment with ACE inhibitors, angiotensin-2 receptor blockers, and diuretics can lower BNP levels.

BNP has several effects, including vasodilation, diuresis, natriuresis, and suppression of both sympathetic tone and the renin-angiotensin-aldosterone system. Clinically, BNP is useful in diagnosing patients with acute dyspnea. A low concentration of BNP (<100 pg/mL) makes a diagnosis of heart failure unlikely, but elevated levels should prompt further investigation to confirm the diagnosis. Currently, NICE recommends BNP as a helpful test to rule out a diagnosis of heart failure. In patients with chronic heart failure, initial evidence suggests that BNP is an extremely useful marker of prognosis and can guide treatment. However, BNP is not currently recommended for population screening for cardiac dysfunction.

The risk of ventricular arrhythmias is increased when amiodarone and erythromycin are used together due to their ability to prolong the QT interval. Manufacturers advise against using multiple drugs that prolong QT interval to avoid this risk. WPW syndrome is a congenital condition that involves abnormal conductive cardiac tissue and can lead to reentrant tachycardia circuit in association with SVT. Amiodarone can cause a slate-grey appearance of the skin, while drugs like rifampicin can cause orange discoloration of body fluids. COPD is associated with multifocal atrial tachycardia.

Amiodarone is a medication used to treat various types of abnormal heart rhythms. It works by blocking potassium channels, which prolongs the action potential and helps to regulate the heartbeat. However, it also has other effects, such as blocking sodium channels. Amiodarone has a very long half-life, which means that loading doses are often necessary. It should ideally be given into central veins to avoid thrombophlebitis. Amiodarone can cause proarrhythmic effects due to lengthening of the QT interval and can interact with other drugs commonly used at the same time. Long-term use of amiodarone can lead to various adverse effects, including thyroid dysfunction, corneal deposits, pulmonary fibrosis/pneumonitis, liver fibrosis/hepatitis, peripheral neuropathy, myopathy, photosensitivity, a ‘slate-grey’ appearance, thrombophlebitis, injection site reactions, and bradycardia. Patients taking amiodarone should be monitored regularly with tests such as TFT, LFT, U&E, and CXR.

A frequent underlying cause of RBBB that persists over time is right ventricular hypertrophy, which may result from the spread of left-sided heart failure to the right side of the heart. Oliver’s shortness of breath is likely due to an accumulation of fluid in the lungs, which can increase pulmonary perfusion pressure and lead to right ventricular strain and hypertrophy. This type of right heart failure that arises from left heart failure is known as cor-pulmonale. While a pulmonary embolism or rheumatic heart disease can also cause right ventricular strain, they are less probable in this case. Myocardial infarction typically presents with chest pain, which is not mentioned in the question stem regarding Oliver’s symptoms.

Right bundle branch block is a frequently observed abnormality on ECGs. It can be differentiated from left bundle branch block by remembering the phrase WiLLiaM MaRRoW. In RBBB, there is a ‘M’ in V1 and a ‘W’ in V6, while in LBBB, there is a ‘W’ in V1 and a ‘M’ in V6.

There are several potential causes of RBBB, including normal variation which becomes more common with age, right ventricular hypertrophy, chronically increased right ventricular pressure (such as in cor pulmonale), pulmonary embolism, myocardial infarction, atrial septal defect (ostium secundum), and cardiomyopathy or myocarditis.

Sleep disturbance is a common side-effect associated with lipid-soluble substances.

Beta-blockers are a class of drugs that are primarily used to manage cardiovascular disorders. They have a wide range of indications, including angina, post-myocardial infarction, heart failure, arrhythmias, hypertension, thyrotoxicosis, migraine prophylaxis, and anxiety. Beta-blockers were previously avoided in heart failure, but recent evidence suggests that certain beta-blockers can improve both symptoms and mortality. They have also replaced digoxin as the rate-control drug of choice in atrial fibrillation. However, their role in reducing stroke and myocardial infarction has diminished in recent years due to a lack of evidence.

Examples of beta-blockers include atenolol and propranolol, which was one of the first beta-blockers to be developed. Propranolol is lipid-soluble, which means it can cross the blood-brain barrier.

Like all drugs, beta-blockers have side-effects. These can include bronchospasm, cold peripheries, fatigue, sleep disturbances (including nightmares), and erectile dysfunction. There are also some contraindications to using beta-blockers, such as uncontrolled heart failure, asthma, sick sinus syndrome, and concurrent use with verapamil, which can precipitate severe bradycardia.

ECG Changes in Myocardial Infarction

When interpreting an electrocardiogram (ECG) in a patient with suspected myocardial infarction (MI), it is important to consider the specific changes that may be present. In the case of a ST-elevation MI (STEMI), the ECG may show ST elevation in affected leads, such as II, III, and aVF. However, it is possible to have a non-ST elevation MI (NSTEMI) with a normal ECG, or with T wave inversion instead of upright T waves.

Other ECG changes that may be indicative of cardiac issues include a prolonged PR interval, which could suggest heart block, and ST depression, which may reflect ischemia. Additionally, tall P waves may be seen in hyperkalemia.

It is important to note that a patient may have an MI without displaying any ECG changes at all. In these cases, checking cardiac markers such as troponin T can help confirm the diagnosis. Overall, the various ECG changes that may be present in MI can aid in prompt and accurate diagnosis and treatment.

An anterior MI is the most probable diagnosis, given the absence of ST changes in the inferior leads. Aortic dissection is therefore less probable.

The following table displays the relationship between ECG changes and the affected coronary artery territories. Anteroseptal changes in V1-V4 indicate involvement of the left anterior descending artery, while inferior changes in II, III, and aVF suggest the right coronary artery is affected. Anterolateral changes in V4-6, I, and aVL may indicate involvement of either the left anterior descending or left circumflex artery, while lateral changes in I, aVL, and possibly V5-6 suggest the left circumflex artery is affected. Posterior changes in V1-3 may indicate a posterior infarction, which is typically caused by the left circumflex artery but can also be caused by the right coronary artery. Reciprocal changes of STEMI are often seen as horizontal ST depression, tall R waves, upright T waves, and a dominant R wave in V2. Posterior infarction is confirmed by ST elevation and Q waves in posterior leads (V7-9), usually caused by the left circumflex artery but also possibly the right coronary artery. It is important to note that a new LBBB may indicate acute coronary syndrome.

Diagram showing the correlation between ECG changes and coronary territories in acute coronary syndrome.

Rheumatic fever is caused by molecular mimicry, where the M protein on the cell wall of Streptococcus pyogenes cross-reacts with myosin in the smooth muscles of arteries, leading to autoimmunity. This is evidenced by the patient’s symptoms of polyarthritis and chest pain, as well as the presence of anti-streptolysin-O-titre in their blood. Bystander activation, exposure to cryptic antigens, and super-antigens are all pathophysiological mechanisms that can lead to autoimmune destruction of tissues.

Rheumatic fever is a condition that occurs as a result of an immune response to a recent Streptococcus pyogenes infection, typically occurring 2-4 weeks after the initial infection. The pathogenesis of rheumatic fever involves the activation of the innate immune system, leading to antigen presentation to T cells. B and T cells then produce IgG and IgM antibodies, and CD4+ T cells are activated. This immune response is thought to be cross-reactive, mediated by molecular mimicry, where antibodies against M protein cross-react with myosin and the smooth muscle of arteries. This response leads to the clinical features of rheumatic fever, including Aschoff bodies, which are granulomatous nodules found in rheumatic heart fever.

To diagnose rheumatic fever, evidence of recent streptococcal infection must be present, along with 2 major criteria or 1 major criterion and 2 minor criteria. Major criteria include erythema marginatum, Sydenham’s chorea, polyarthritis, carditis and valvulitis, and subcutaneous nodules. Minor criteria include raised ESR or CRP, pyrexia, arthralgia, and prolonged PR interval.

Management of rheumatic fever involves antibiotics, typically oral penicillin V, as well as anti-inflammatories such as NSAIDs as first-line treatment. Any complications that develop, such as heart failure, should also be treated. It is important to diagnose and treat rheumatic fever promptly to prevent long-term complications such as rheumatic heart disease.

The histology findings of a myocardial infarction (MI) vary depending on the time elapsed since the event. Within the first 24 hours, early coagulative necrosis, neutrophils, wavy fibres, and hypercontraction of myofibrils are observed, which increase the risk of ventricular arrhythmia, heart failure, and cardiogenic shock. Between 1-3 days post-MI, extensive coagulative necrosis and neutrophils are present, which can lead to fibrinous pericarditis. From 3-14 days post-MI, macrophages and granulation tissue are seen at the margins, and there is a high risk of complications such as free wall rupture (resulting in mitral regurgitation), papillary muscle rupture, and left ventricular pseudoaneurysm. Finally, from 2 weeks to several months post-MI, a contracted scar is formed, which is associated with Dressler syndrome, heart failure, arrhythmias, and mural thrombus.

Myocardial infarction (MI) can lead to various complications, which can occur immediately, early, or late after the event. Cardiac arrest is the most common cause of death following MI, usually due to ventricular fibrillation. Cardiogenic shock may occur if a large part of the ventricular myocardium is damaged, and it is difficult to treat. Chronic heart failure may result from ventricular myocardium dysfunction, which can be managed with loop diuretics, ACE-inhibitors, and beta-blockers. Tachyarrhythmias, such as ventricular fibrillation and ventricular tachycardia, are common complications. Bradyarrhythmias, such as atrioventricular block, are more common following inferior MI. Pericarditis is common in the first 48 hours after a transmural MI, while Dressler’s syndrome may occur 2-6 weeks later. Left ventricular aneurysm and free wall rupture, ventricular septal defect, and acute mitral regurgitation are other complications that may require urgent medical attention.

ST elevation is expected in the leads corresponding to the affected part of the heart in an STEMI, while ST depression, T wave inversion, or no change is expected in an NSTEMI or angina. Dilated cardiomyopathy does not have any classical ECG changes, and it is not commonly associated with hypertension as LVF. LVF, on the other hand, causes left ventricular hypertrophy due to prolonged hypertension, resulting in an increase in R-wave amplitude in leads 1, aVL, and V4-6, as well as an increase in S wave depth in leads III, aVR, and V1-3 on the right side.

ECG Indicators of Atrial and Ventricular Hypertrophy

Left ventricular hypertrophy is indicated on an ECG when the sum of the S wave in V1 and the R wave in V5 or V6 exceeds 40 mm. Meanwhile, right ventricular hypertrophy is characterized by a dominant R wave in V1 and a deep S wave in V6. In terms of atrial hypertrophy, left atrial enlargement is indicated by a bifid P wave in lead II with a duration of more than 120 ms, as well as a negative terminal portion in the P wave in V1. On the other hand, right atrial enlargement is characterized by tall P waves in both II and V1 that exceed 0.25 mV. These ECG indicators can help diagnose and monitor patients with atrial and ventricular hypertrophy.